Moderna shares rose 13% to a year-to-date high as R&D positives were released ahead of earnings
BIBIBI
AT A GLANCE
Moderna's stock price rose by about 13.1%, with two pieces of R&D news drawing attention, and trading in MRNA contracts on Hyperliquid also heated up in tandem.
Article
Moderna released positive R&D news before its earnings report, and the stock rose 13% to hit a new high for the year.
BlockBeats news, November 5, Moderna's stock closed up about 13.1%, about 5.11% above the 52-week high set earlier on October 21. The company is about to release its third-quarter earnings report on November 6, and the market is also watching progress in its vaccine business and oncology therapy development.
In terms of news, the Ebola vaccine candidate mRNA-1469 was recommended by a WHO technical advisory group to advance to Phase II/III studies, and early clinical data for another multiple myeloma candidate therapy, mRNA-2808, was also selected for an oral presentation at the American Society of Hematology annual meeting.
According to TradingBeats monitoring, the MRNA contract on Hyperliquid briefly touched 268.31 USD this morning, and at press time the price was temporarily reported at 257.05 USD. Trading activity rose at the same time.
Its 24-hour trading volume rose from about 20480000 USD at the same time yesterday to 48020000 USD, an increase of about 134.5%; notional open interest rose from 21290000 USD to 27400000 USD, an increase of about 6110000 USD, or 28.7%.
The rise put pressure on large short positions. The largest short still holds about 11580000 USD in MRNA short positions, with an average price of about 211 USD and a current floating loss of about 2086000 USD.
Address:
Original link https://m.theblockbeats.info/flash/375618
Key points
01
November 5, Moderna stock closed up approximately 13.1%.
02
The stock price is about 5.11% higher than the 52-week high set on October 21.
03
The company will announce its third-quarter earnings report on November 6.
04
The Ebola vaccine candidate mRNA-1469 has been recommended by a WHO technical advisory group to advance to Phase II/III studies.
05
Early clinical data for the multiple myeloma candidate therapy mRNA-2808 were selected as an oral presentation at the American Society of Hematology Annual Meeting.
06
According to monitoring by TradingBeats, the MRNA contract on Hyperliquid briefly touched 268.31 USD this morning and was temporarily quoted at 257.05 USD at press time.
07
MRNA contract 24-hour trading volume rose from about 20480000 USD to 48020000 USD, an increase of about 134.5%.
08
Nominal open interest value rose from 21290000 USD to 27400000 USD, an increase of approximately 6110000 USD, up 28.7%.
09
The largest short position holds about 11580000 USD MRNA short, with an average price of about 211 USD, and currently has an unrealized loss of about 2086000 USD.
AI-assisted interpretation
The following is analysis, separate from reported facts. Verify important claims independently.
This news involves the company's stock, R&D progress, and the MRNA contract on Hyperliquid. The rise in stock price and contract trading activity indicates increased market attention; the candidate vaccine being recommended for further research and the candidate therapy data being selected for conference presentation mean that the projects have gained opportunities for continued demonstration or research, but this does not mean that the therapy has been approved or clinically successful.
Why it matters to readers
Moderna is about to release its third-quarter earnings report, and the market remains focused on the vaccine business and oncology therapy research and development. Meanwhile, MRNA contract trading volume and open interest value have increased, meaning that the capital and positions involved in trading have expanded, and price volatility may become more pronounced.
Beginners should distinguish between Moderna stock and the MRNA contract on Hyperliquid. Contracts may involve leverage, and an increase in open positions can amplify both profits and losses; a research and development project advancing to the next research phase or being presented at an academic conference also cannot be directly regarded as commercial success.
Risks and unknowns
The R&D progress in the report mainly comes from media retellings, and the original text does not provide official documents from WHO or the American Society of Hematology.
The Hyperliquid contract prices, trading volume, open interest, and short position data come from TradingBeats monitoring; the original text did not provide independent verification materials.
Related Developments
Loading event timeline…
The original text only writes November 5 and November 6, without specifying the year.
The contents of the third quarter financial report and its impact on market prices have not yet been announced.
The follow-up research results, regulatory progress, and commercialization prospects for mRNA-1469 and mRNA-2808 remain unclear.
Related concepts
Candidate vaccine
This term is not in the glossary yet. Browse related concepts in the glossary.
